Cargando…
Leukocyte telomere length and plasma interleukin-1β and interleukin-18 levels in mild cognitive impairment and Alzheimer’s disease: new biomarkers for diagnosis and disease progression?
Autores principales: | Corbo, Rosa Maria, Businaro, Rita, Scarabino, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8284289/ https://www.ncbi.nlm.nih.gov/pubmed/33318425 http://dx.doi.org/10.4103/1673-5374.300986 |
Ejemplares similares
-
Can leukocyte telomere shortening be a possible biomarker to track Huntington’s disease progression?
por: Mantuano, Elide, et al.
Publicado: (2019) -
Leukocyte Telomere Length as Potential Biomarker of HD Progression: A Follow-Up Study
por: Scarabino, Daniela, et al.
Publicado: (2022) -
Analysis of the Association Between TERC and TERT Genetic Variation and Leukocyte Telomere Length and Human Lifespan—A Follow-Up Study
por: Scarabino, Daniela, et al.
Publicado: (2019) -
Leukocyte Telomere Length Variability as a Potential Biomarker in Patients with PolyQ Diseases
por: Scarabino, Daniela, et al.
Publicado: (2022) -
The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease
por: Liang, Chih-Sung, et al.
Publicado: (2020)